Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C

Hepatology Research

Volumn 40, Issue 8, 2010, Pages 757-762

  Matsui, Keiji ^a   Iwabuchi, Shogo ^a   Shimizu, Hirohito ^a   Yoshida, Atsushi ^a   Fujikawa, Tomoaki ^a   Takatsuka, Kentaro ^a  

^a Ofuna Chuo Hospital   (Japan)

Author keywords

Gompertzian model; Hepatitis C virus; Induction therapy; Interferon beta

Indexed keywords

BETA INTERFERON; HEPATITIS C ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77955239105     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00669.x     Document Type: Article

References (17)

1. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008, 14:1652-6.
2. Hezode C, Forestier N, Dusheiko G. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-50.
3. Okushin H, Morii K, Kishi F, Yuasa S. Efficacy of the combination therapy using twice-a-day IFN-beta followed by IFN alpha-2b in treatment for chronic hepatitis C. Kanzo 1997, 38:11-8.
4. Enomoto S, Tamai H, Oka M. Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level. Hepatol Res 2007, 37:692-700.
5. Furusyo N, Hayashi J, Ohmiya M. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999, 44:608-17.
6. Moreno-Otero R, Trapero-Marugan M, Gomez-Dominguez E, Garcia-Buey L, Moreno-Monteagudo JA. Is interferon-beta an alternative treatment for chronic hepatitis C? World J Gastroenterol 2006, 12:2730-6.
7. Nakajima H, Shimomura H, Iwasaki Y. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin. Acta Med Okayama 2003, 57:217-25.
8. Saito H, Tada S, Ebinuma H. Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Keio J Med 2006, 55:111-7.
9. Asahina Y, Izumi N, Uchihara M. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001, 34:377-84.
10. Izumi N, Kumada H, Hashimoto N. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Dig Dis Sci 2001, 46:516-23.
11. Matsui K. A verification of the assumptive thesis, "HCV kinetics is conform to Gompertzian model" Kanzo 2009, 50:324-38.
12. Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos Trans R Soc Lond 1825, 115:513-85.
13. Akuta N, Suzuki F, Kawamura Y. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007, 50:361-8.
14. Enomoto N, Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 2010, 53:66-9.
15. Tanaka Y, Nishida N, Sugiyama M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-9.
16. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003, 327:1459-61.
17. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-92.